An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life of GERD in Patients With Erosive Gastroesophageal Reflux Disease.

AstraZeneca1 site in 1 country2,001 target enrollmentJune 2006

ConditionsGERD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: GERD
Sponsor: AstraZeneca
Enrollment: 2001
Locations: 1
Primary Endpoint: To gather epidemiological data in a population of GERD patients
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this study is to gather epidemiological data in a population of GERD patients in primary care with a history of erosive esophagitis (less than or equal to 3 years).

Registry

clinicaltrials.gov

Start Date

June 2006

End Date

March 2008

Last Updated

14 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with erosive esophagitis (endoscopical findings according to the Los Angeles Classification; grade A-D) currently not treated with a proton pump inhibitor, for whom the general practitioner (GP) has decided to initiate or change the treatment for GERD

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

To gather epidemiological data in a population of GERD patients

Time Frame: After collection of all questionnaires

Secondary Outcomes

To evaluate the added value of a new patient questionnaire (GERD Impact Scale) as a useful tool for the initial and long-term management of GERD patients: determination of the appropriate treatment and evaluation of the response to treatment.(After collection of all questionnaires)